News
SPRO
1.010
-5.61%
-0.060
*Spero Therapeutics Appoints William Ho to Its Bd of Directors
Dow Jones · 9h ago
Press Release: Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors
Dow Jones · 10h ago
Weekly Report: what happened at SPRO last week (1102-1106)?
Weekly Report · 1d ago
Alphabet maintains massive SpaceX bet, initiates $548M Qualcomm stake
Seeking Alpha · 1d ago
Weekly Report: what happened at SPRO last week (1026-1030)?
Weekly Report · 11/02 09:42
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
Benzinga · 10/29 18:32
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Korro Bio (KRRO) and Spero Therapeutics (SPRO)
TipRanks · 10/29 08:50
Cantor Fitzgerald Initiates Coverage of Spero Therapeutics at Overweight
NASDAQ · 10/29 02:26
This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Benzinga · 10/28 12:38
Spero Therapeutics Price Target Announced at $6.00/Share by Cantor Fitzgerald
Dow Jones · 10/28 10:46
Cantor Fitzgerald Initiates Coverage On Spero Therapeutics with Overweight Rating, Announces Price Target of $6
Benzinga · 10/28 10:35
Spero Therapeutics initiated with an Overweight at Cantor Fitzgerald
TipRanks · 10/28 10:06
Spero Therapeutics, Inc. Announces Retirement of Chief Operating Officer Timothy Keutzer
NASDAQ · 10/28 03:38
Spero Therapeutics announces planned COO retirement and transition
TipRanks · 10/27 21:50
Spero Therapeutics COO Timothy Keutzer to retire
TipRanks · 10/26 12:26
Press Release: Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
Dow Jones · 10/26 12:00
Weekly Report: what happened at SPRO last week (1019-1023)?
Weekly Report · 10/26 09:42
Weekly Report: what happened at SPRO last week (1012-1016)?
Weekly Report · 10/19 09:42
Weekly Report: what happened at SPRO last week (1005-1009)?
Weekly Report · 10/12 09:45
Weekly Report: what happened at SPRO last week (0928-1002)?
Weekly Report · 10/05 09:45
More
Webull provides a variety of real-time SPRO stock news. You can receive the latest news about Spero Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.